Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
6 evidence topics · 6 sources
Urothelial carcinogen exposure and detoxification
Field defect and multifocal disease
Molecular drivers and transcriptomic classes of NMIBC
“Activating mutations in FGFR3 and PIK3CA and chromosome 9 deletions have been identified as early disease drivers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecular subtypes associated with response and failure after BCG
“Here we conducted molecular profiling of 132 patients with BCG-naïve HR-NMIBC and 44 patients with recurrences after BCG (34 matched), which uncovered three distinct BCG response subtypes (BRS1–3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with BRS3 tumors had reduced recurrence and progression-free survival compared to BRS1/2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BRS3 tumors expressed high EMT-basal markers and had an immunosuppresive profile, which was confirmed with spatial proteomics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BRS3-predicted tumors were enriched in post-BCG 28/44 (64%) recurrences vs pre-BCG tumors 82/283 (28%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From the 34 matched tumors, 26/34 patients had BRS1/ 2 tumors pre-BCG of which 14/26 tumors switched to BRS3 post-BCG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adaptive immune resistance as a mechanism of BCG failure
“The final cohort contained 63 pretreatment NMIBC cases, including 31 BCG responders and 32 BCG nonresponders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline PD-L1 expression (22C3 and SP-142) was observed in 25% to 28% of nonresponders and 0% to 4% of responders (P < 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PD-L1+ cells in BCG nonresponders colocalized with CD8+ T cells.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One mechanism of BCG failure may be adaptive immune resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote